Beyond Glucose: How Continuous Multi‑Biomarker Monitoring Is Reshaping Metabolic Health

In recent years, patients' approaches to managing diabetes have shifted markedly as wearable devices such as continuous glucose monitors (CGMs) increasingly replace traditional finger‑prick tests. These sensors provide real‑time data that help people and clinicians make faster, more informed decisions about therapy and lifestyle.

There are now early moves to broaden continuous monitoring beyond glucose. Abbott's Libre Duo — a 10‑day dual glucose–ketone monitor — received a CE mark in May 2026 and US Food and Drug Administration (FDA) approval in August 2026, becoming the first glucose–ketone monitor to reach the diabetes market. This milestone highlights the expanding scope of metabolic monitoring technology.

In the latest GlobalData Healthcare podcast, Medical Device Network reporter Annabel Kartal‑Allen speaks with Jared Tangney, co‑founder, president and chief technology officer of BioLinq, about the current and future role of continuous monitoring devices. Tangney discusses both the immediate implications for diabetes management and the broader potential for other metabolic conditions such as obesity.

Expanding the Biomarker Toolbox

Tangney emphasizes the value of continuously measuring additional biomarkers alongside glucose — including ketones, cortisol and lactate. Combining these signals can paint a richer picture of metabolic state: ketones indicate fuel use and energy balance, cortisol reflects stress and circadian influences, and lactate can signal exercise and metabolic stress. Together, multi‑biomarker data streams could enable more personalized treatment adjustments, earlier detection of metabolic deterioration, and tailored lifestyle interventions.

Opportunities and Challenges

Multi‑analyte continuous monitoring promises meaningful clinical and consumer benefits, but also raises challenges. Device accuracy, sensor longevity, calibration needs, data interpretation, regulatory pathways and patient privacy are all important considerations. Integrating multiple continuous signals into clinical workflows and consumer apps will require robust algorithms, clear clinical validation, and education for healthcare professionals and users.

The podcast episode explores how richer, continuous biomarker data could change both clinical practice and personal health management — shifting care from reactive to proactive and enabling more precise, individualized decisions about medication, diet and activity.

This episode is part of the GlobalData Healthcare podcast series, which covers medical devices, biotech, pharma and clinical trials.